iRhythm Holdings IRTC
iRhythm Holdings reported a $29.85 million net loss
Quarterly report for the period ended Sep 30, 2026, 8 new risk factors
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001388658-26-000094
- Revenue of $221.59 million for the three months ended Sep 30, 2026
- Diluted EPS of -$0.90 for the three months ended Sep 30, 2026
- Cash and equivalents of $394.72 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
8 new risk factors · 5 removed · 15 new legal mentions
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change QoQ | |
|---|---|---|---|
| Revenue | $221.59M | $224.17M | −1.2% |
| Operating income and margin | −$32.56M · -14.7% | −$2.54M · -1.1% | −1181%, margin −13.6 pts |
| Net income | −$29.85M | −$381K | −7735% |
| Operating cash flow | $4.44M | $51.08M | −91% |
| Cash | $394.72M | $246.68M | +60% |
New risk factors (8)
- • Our revenue relies on orders for our remote cardiac monitoring solutions. If our current or future remote cardiac monitoring solutions fail to gain, or lose, market acceptance, our business will suffer.
- • We may fail to realize the anticipated benefits of our acquisition of VitalConnect or those benefits may take longer to realize than expected, and we may encounter significant integration difficulties in addition to the legal and compliance risks present for companies such as VitalConnect, many of which are…
- • Our indebtedness could adversely affect our financial health and our ability to respond to changes in our business; increasing our financial leverage could affect our operations and profitability; and failure to comply with covenants in our senior secured revolving credit agreement could result in our inability to…
- We may fail to realize the anticipated benefits of our acquisition of VitalConnect or those benefits may take longer to realize than expected, and we may encounter significant integration difficulties in addition to the legal and compliance risks present for companies such as VitalConnect, many of which are… +4 more paragraphs
- We continue to devote time and resources into commercializing the sleep apnea screening and diagnostics market, which carries unique regulatory requirements, as well as coding and reimbursement policies that remain in flux, and remains an ongoing area of focus for government enforcement. +1 more paragraph
- and 3 more in the filing
Removed risk factors (5)
- • Our revenue relies on orders for our iRhythm Services, which are currently our only offerings. If our iRhythm Services or future service offerings fail to gain, or lose, market acceptance, our business will suffer.
- In August 2026, we announced our pending acquisition of Vital Connect, Inc. ("VitalConnect"). Completion of the transaction is subject to the satisfaction of closing conditions, including receipt of required regulatory approval. There can be no assurance that the transaction will be completed on the anticipated terms…
- We are currently exploring opportunities to expand into the market of sleep apnea screening and diagnostics, which carries unique regulatory requirements and represents an ongoing area of focus for government enforcement. Commercialization of new products and services in the sleep testing space will require a… +1 more paragraph
- • our ability to scale our manufacturing operations to meet demand for the iRhythm ACM Systems used in our current and any future iRhythm Services or other offerings;
- As a result of our increased level of debt following the completion of the 2024 offering by our predecessor and now wholly owned subsidiary, iRhythm Technologies, of 1.50% Convertible Senior Notes due 2029 of our wholly owned subsidiary, iRhythm Technologies, (the "2029 Notes"), of which we have provided a full and…
New legal mentions (15)
- On June 3, 2026, iRhythm Technologies entered into a binding Stipulation and Agreement of Settlement (the "Securities Settlement Agreement") to fully resolve the putative class action securities litigation originally filed in the United States District Court for the Northern District of California in February 2024…
- In August 2026, the Company and its insurance carriers funded an escrow settlement account for $ 45.0 million, of which the insurance carriers and the Company funded $ 35.0 million and $ 10.0 million, respectively, with the Company's portion recorded as restricted cash – current within its unaudited condensed…
- As a result, during the three and nine months ended September 30, 2026, the Company recorded litigation settlement expense, net of expected insurance recoveries, relating to the Securities Settlement Agreement of approximately $( 0.2 ) million and $ 13.7 million, respectively, in the accompanying unaudited condensed…
- The cases make similar allegations to those in the securities class action complaint described above and the parties are evaluating next steps in light of the settlement in the securities action.
- On November 4, 2026, the Company met with the DOJ to discuss the status of the matters and to discuss potential resolution pathways. +1 more paragraph
- and 10 more in the filing
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- Merit Medical Systems MMSI public float $5.4B, Jun 30, 2025
- TransMedics Group TMDX public float $4.4B, Jun 30, 2025
- Integer Holdings ITGR public float $4.3B, Jun 27, 2025
- GLAUKOS GKOS public float $5.9B, Jun 30, 2025
- Masimo MASI public float $3.9B, Jun 28, 2025